1.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VION-CLI-024, MCC-13110, MCC-IRB-100798, NCT00054015
|
|
2.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VION-CLI-031, NCT00064051
|
|
3.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VION-CLI-030, MDA-ID-030143, NCT00064064
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 90
Sponsor: NCI
Protocol IDs: AECM-0803945, NCI-6254, NCT00075504, 6254
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CAN-NCIC-IND161, NCI-NCIC-161, NCIC-161, NCT00075660, IND161
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1503, E1503, NCT00077350
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CTRG-LUN012, NCI-6256, NCT00077415, 6256
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-12765A, NCI-6285, NCT00077545, 6285
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: PMH-PHL-023, NCI-6271, 6271, NCT00078975
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-0126O, NCT00081276
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC0345, 6293, NCI-6293, NCT00085371
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC0333, 6292, NCI-6292, NCT00095888
|
|
13.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VION-CLI-001-01, NCI-V99-1578
|
|
14.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VION-CLI-001-2, NCI-V99-1579, NCT00004213
|
|
15.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: VION-CLI-009, AECM-12000041110, NCI-V00-1598, NCT00006218
|
|
16.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VION-CLI-015, AECM-1200012380, NCI-V01-1658, NCT00016874
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VION-CLI-021, NCI-V01-1668, NCT00024323
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VION-CLI-032, MDA-DM-030096, NCT00064090
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-12806B, NCI-6283, NCT00077181, 6283
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: JHOC-J0357, NCI-6255, NCT00077558, 6255
|
|
21.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: WCCC-CO-03904, NCI-6266, NCT00079014, 6266
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: WCCC-CO-03903, NCI-6264, 6264, NCT00084877
|
|
23.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CASE-1805, 7336, NCI-7336, CASE-110534, NCT00335998
|
